Comparison · NCT00858013-b3147ead
Nateglinide vs Glimepiride: The Durability of Nateglinide in Comparison With Those of Glimepiride Based on the Withdrawal Rate
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nateglinide vs Glimepiride: The Durability of Nateglinide in Comparison With Those of Glimepiride Based on the Withdrawal Rate. Trial comparisons, record NCT00858013-b3147ead. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00858013-b3147ead
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.417 | 0.245 | 0.612 | wilson | |
| Risk in group 2 | 0.304 | 0.156 | 0.509 | wilson | |
| Risk difference, group 1 minus group 2 | 0.112 | -0.155 | 0.357 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.37 | 0.629 | 2.98 | log | |
| Odds ratio, group 1 over group 2 | 1.63 | 0.49 | 5.44 | log | |
| Number needed to treat, for one more participant with the outcome on Nateglinide than on Glimepiride | 8.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nateglinide | Nateglinide 90\~120mg three times a day~Nateglinide: Nateglinide 90\~120mg three times a day | 10 | 24 | OG000 |
| Group 2 | Glimepiride | Glimepiride 1\~2mg once a day~Glimepiride: Glimepiride 1\~2mg once a day | 7 | 23 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- The Durability of Nateglinide in Comparison With Those of Glimepiride Based on the Withdrawal Rate
- Description
- % monotherapy failure, that means % number of participants who withdrew from the study due to high HbA1c (\>8.0%)
- Time frame
- every 3 months following randomization, for 24 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- Study of the Durability of Glycemic Control With Nateglinide
- NCT number
- NCT00858013
- Phases
- PHASE4
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Nateglinide, Glimepiride
- Lead sponsor
- Ajou University School of Medicine
- Results first posted
- 2017-03-31
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00858013?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00858013-b3147ead